Situación actual de la dislipemia en España: La visión del cardiólogo

Go, 2014, Heart disease and stroke statistics--2014 update: a report from the American Heart Association, Circulation., 129, e28, 10.1161/01.cir.0000441139.02102.80 Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet., 364, 937, 10.1016/S0140-6736(04)17018-9 Cordero, 2012, Los niveles bajos de colesterol HDL se asocian de forma independiente a enfermedad coronaria aguda en pacientes que ingresan por dolor torácico, Rev Esp Cardiol., 65, 319, 10.1016/j.recesp.2011.07.022 Reiner, 2011, ESC/EAS. Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) the European Atherosclerosis Society (EAS)., Eur Heart J., 32, 1769, 10.1093/eurheartj/ehr158 Stone, 2014, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol., 63, 2889, 10.1016/j.jacc.2013.11.002 Bertomeu, 2009, Control de los factores de riesgo y tratamiento de la cardiopatía isquémica: Registro TRECE, Rev Esp Cardiol., 62, 807, 10.1016/S0300-8932(09)71694-X Cordero, 2013, Patients with cardiac disease: Changes observed through last decade in out-patient clinics, World J Cardiol., 5, 288, 10.4330/wjc.v5.i8.288 Reiner, 2013, Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey, Atherosclerosis., 231, 300, 10.1016/j.atherosclerosis.2013.09.020 Gitt, 2012, Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada, Eur J Prev Cardiol., 19, 221, 10.1177/1741826711400545 Gabriel, 2008, Prevalencia, distribución y variabilidad geográfica de los principales factores de riesgo cardiovascular en España, Análisis agrupado de datos individuales de estudios epidemiológicos poblacionales: estudio ERICE. Rev Esp Cardiol., 61, 1030 Grau, 2011, Factores de riesgo cardiovascular en España en la primera década del siglo XXI: análisis agrupado con datos individuales de 11 estudios de base poblacional, estudio DARIOS, Rev Esp Cardiol., 64, 295, 10.1016/j.recesp.2010.11.005 Guallar-Castillon, 2012, Magnitud y manejo de la hipercolesterolemia en la población adulta de España, 2008-2010: el estudio ENRICA, Rev Esp Cardiol., 65, 551, 10.1016/j.recesp.2012.02.005 Foody, 2005, Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE), Am J Cardiol., 95, 483, 10.1016/j.amjcard.2004.09.060 Ferreira-Gonzalez, 2008, Estudio MASCARA.(Manejo del Síndrome Coronario Agudo Registro Actualizado). Resultados globales, Rev Esp Cardiol., 61, 803, 10.1157/13124991 Cho, 2010, Low-density lipoprotein cholesterol level in patients with acute myocardial infarction having percutaneous coronary intervention (the cholesterol paradox), Am J Cardiol., 106, 1061, 10.1016/j.amjcard.2010.06.009 Aros, 2011, Reducción de la mortalidad precoz, a 6 meses en pacientes con IAM en el periodo 1995-2005., Datos de los registros PRIAMHO I, II y MASCARA. Rev Esp Cardiol., 64, 972 Cordero, 2012, Características clínicas, evolución hospitalaria de los pacientes con síndrome coronario agudo en función del tabaquismo, Med Clin (Barc)., 138, 422, 10.1016/j.medcli.2011.01.016 Lopez de Sa, 2011, Uso de antagonistas de los receptores de aldosterona tras el infarto de miocardio Datos del registro, REICIAM. Rev Esp Cardiol., 64, 981, 10.1016/j.recesp.2011.06.013 Elbarouni, 2012, Temporal patterns of lipid testing and statin therapy in acute coronary syndrome patients (from the Canadian GRACE Experience), Am J Cardiol., 109, 1418, 10.1016/j.amjcard.2012.01.352 Oduncu, 2013, The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naive patients undergoing primary percutaneous coronary intervention, Int J Cardiol., 167, 458, 10.1016/j.ijcard.2012.01.009 Morillas, 2009, Prognostic value of low ankle-brachial index in patients with hypertension and acute coronary syndromes, J Hypertens., 27, 341, 10.1097/HJH.0b013e3283199193 Cordero, 2013, Perfil clínico y pronóstico de los pacientes con síndrome coronario agudo, colesterol unido a lipoproteínas de baja densidad < 70mg/dl., Rev Esp Cardiol., 66, 588, 10.1016/j.recesp.2013.01.012 Bueno, 2005, Manejo del síndrome coronario agudo sin elevación del segmento ST en España, Estudio DESCARTES (Descripción del Estado de los Síndromes Coronarios Agudos en un Registro Temporal ESpañol). Rev Esp Cardiol., 58, 244 Fyfe, 1971, Plasma-lipid changes after myocardial infarction, Lancet., 2, 997, 10.1016/S0140-6736(71)90322-9 Sniderman, 1977, Predictable changes in low density lipoprotein composition after acute myocardial infarction, Atherosclerosis., 27, 361, 10.1016/0021-9150(77)90046-6 Rosenson, 1993, Myocardial injury: the acute phase response and lipoprotein metabolism, J Am Coll Cardiol., 22, 933, 10.1016/0735-1097(93)90213-K Pitt, 2008, Lipid levels after acute coronary syndromes, J Am Coll Cardiol., 51, 1440, 10.1016/j.jacc.2007.11.075 Perk, 2012, European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)., Eur Heart J., 33, 1635, 10.1093/eurheartj/ehs092 Bayturan, 2010, Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol, J Am Coll Cardiol., 55, 2736, 10.1016/j.jacc.2010.01.050 Crea, 2013, Pathogenesis of acute coronary syndromes, J Am Coll Cardiol., 61, 1, 10.1016/j.jacc.2012.07.064 Law, 1999, Attribution of time lag theory to explain French paradox, BMJ, 319, 1073, 10.1136/bmj.319.7216.1073 Degano, 2013, Estabilidad de la placa aterosclerótica y la paradoja del sur de Europa, Rev Esp Cardiol., 66, 56, 10.1016/j.recesp.2012.07.014 Fácila, 2012, Lipoproteínas de alta densidad tras un síndrome coronario agudo, evaluando el riesgo residual, Rev Esp Cardiol., 1, 66 Medrano, 2007, Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española, Rev Esp Cardiol., 60, 1250, 10.1157/13113930 Narula, 2013, Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques, J Am Coll Cardiol., 61, 1041, 10.1016/j.jacc.2012.10.054 Puri, 2013, Factors underlying regression of coronary atheroma with potent statin therapy, Eur Heart J., 34, 1818, 10.1093/eurheartj/eht084 Nissen, 2007, Effect of very high-intensity statin therapy on regression of coronary atherosclerosis, J.A.M.A., 295, 1556, 10.1001/jama.295.13.jpc60002 Stone, 2011, A prospective natural-history study of coronary atherosclerosis, N Engl J Med., 364, 226, 10.1056/NEJMoa1002358 Puri, 2013, Coronary atheroma volum cardiovascular events during maximally intensive statin therapy, Eur Heart J., 34, 3182, 10.1093/eurheartj/eht260 Moreno, 2014, Thinking outside the lumen: fractional flow reserve versus intravascular imaging for major adverse cardiac event prediction, J Am Coll Cardiol., 63, 1141, 10.1016/j.jacc.2013.07.072 Marrugat, 2003, Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada, Rev Esp Cardiol., 56, 253, 10.1016/S0300-8932(03)76861-4 Sans, 2007, Calibración de la tabla SCORE de riesgo cardiovascular para España, Rev Esp Cardiol., 60, 476, 10.1016/S0300-8932(07)75064-9 Mcgorrian, 2011, Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART.Modifiable Risk Score, Eur Heart J., 32, 581, 10.1093/eurheartj/ehq448 Cordero, 2014, Valor pronóstico de la escala INTERHEART-colesterol para pacientes que ingresan por dolor torácico, Rev Esp Cardiol., 67, 578, 10.1016/j.recesp.2014.02.013 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet., 376, 1670, 10.1016/S0140-6736(10)61350-5 Gonzalez-Juanatey, 2011, Prevalencia y características de la dislipemia en pacientes en prevención primaria, secundaria tratados con estatinas en España, Estudio DYSIS-España. Rev Esp Cardiol., 64, 286, 10.1016/j.recesp.2010.10.030 Perez de Isla, 2013, Alvarez-Sala, et alCifras de colesterol adecuadas en pacientes coronarios y diabéticos. Análisis según especialidades médicas y comunidades autónomas, Rev Esp Cardiol., 66, 748, 10.1016/j.recesp.2013.04.012 Kotseva, 2009, Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE III, and III surveys in eight European countries, Lancet., 373, 929, 10.1016/S0140-6736(09)60330-5 Ferrieres, 2009, Patterns of statin prescription in acute myocardial infarction: the French registry of Acute ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI), Atherosclerosis., 204, 491, 10.1016/j.atherosclerosis.2008.09.031 Nicholls, 2011, Effect of two intensive statin regimens on progression of coronary disease, N Engl J Med., 365, 2078, 10.1056/NEJMoa1110874 Lee, 2011, Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol, J Am Coll Cardiol., 58, 1664, 10.1016/j.jacc.2011.05.057 Cannon, 2004, Intensive versus moderate lipid lowering with statins after acute coronary syndromes, N Engl J Med., 350, 1495, 10.1056/NEJMoa040583 Pedersen, 2005, Incremental Decrease in End Points through Aggressive Lipid Lowering Study G, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL. study: a randomized controlled trial. J.A.M.A., 294, 2437 Stone, 2014, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the ACC/AHA Task Force on Practice Guidelines, J Am Coll Cardiol., 63, :2889, 10.1016/j.jacc.2013.11.002 Cannon, 2008, design of IMPROVE-IT.(IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes, Am Heart J., 156, 826, 10.1016/j.ahj.2008.07.023 Ruiz-Nodar, 2010, Impacto del tipo de hospital en el tratamiento y evoluciónn de los pacientes con síndrome coronario agudo sin elevación del ST, Rev Esp Cardiol., 63, 390, 10.1016/S0300-8932(10)70059-2 Quiles, 2011, Combination of ankle brachial index and diabetes mellitus to predict cardiovascular events and mortality after an acute coronary syndrome, Int J Cardiol., 151, 84, 10.1016/j.ijcard.2010.04.097 Vivas, 2014, Efecto del tratamiento optimizado con insulina en la reactividad plaquetaria tras el alta de pacientes hiperglucémicos con síndrome coronario agudo, Rev Esp Cardiol., 67, 22, 10.1016/j.recesp.2013.05.021 Cordero, 2009, Differences in medical treatment of chronic coronary heart disease patients according to medical specialities, Cardiovasc Ther., 27, 173, 10.1111/j.1755-5922.2009.00093.x González-Juanatey, 2011, Magnitud y características del riesgo residual lipídico en pacientes con antecedentes de revascularización coronaria: estudio ICP-Bypass, Rev Esp Cardiol., 64, 862, 10.1016/j.recesp.2011.05.022 Bhatt, 2006, International prevalence recognition treatment of cardiovascular risk factors in outpatients with atherothrombosis., JAMA, 295, 180, 10.1001/jama.295.2.180 Javed, 2010, Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG), Am Heart J., 160, 1130, 10.1016/j.ahj.2010.08.041 Utilización de medicamentos hipolipemiantes en España durante el periodo 2000-2012. Disponible en: http://www.aemps.gob.es Cordero, 2011, Clustering of target organ damage increases mortality after acute coronary syndromes in patients with arterial hypertension, J Hum Hypertens., 25, 600, 10.1038/jhh.2010.109